Kahn Swick & Foti, LLC Investigates the Officers and Directors of DexCom, Inc. - DXCM

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into DexCom, Inc. (“DexCom” or the “Company”) (NasdaqGS: DXCM).

On July 25, 2024, the Company announced its financial results for the second quarter of fiscal 2024, disclosing reduced revenue guidance for the full fiscal year 2024 due in part to the execution of "several key strategic initiatives" which "did not meet [their] high standards" and slower-than-expected new customer growth in the durable medical equipment sector.

Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing.

KSF’s investigation is focusing on whether DexCom’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.

If you have information that would assist KSF in its investigation, or have been a long-term holder of DexCom shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ([e-mail]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-dxcm/ to learn more.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago and New Jersey.

To learn more about KSF, you may visit www.ksfcounsel.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241221909614/en/

The Dexcom Stock at the time of publication of the news with a raise of +4,98 % to 76,77EUR on Tradegate stock exchange (20. Dezember 2024, 22:26 Uhr).